Our current research focuses on:

  • Cancer vaccines exploiting the in vivo delivery of tumour specific (neo-)antigens to cross-presenting dendritic cells to improve the immunotherapy for melanoma, breast cancer, lymphoma, glioblastoma and virus-driven tumours.
  • Development and validation of clinically applicable protocols for the identification of tumour-specific immunogenic neo-epitopes to be exploited in personalised vaccination approaches.
  • Identify and validate new classes of tumour antigens that can constitute suitable targets for immunotherapy in various types of cancers.
  • Assessment of the clinical relevance of anti-tumour immune responses in cancer patients treated with immunomodulating treatments